“We really want to be a strong partner for our blood center customers in helping them deliver their important mission, which is to provide safe blood for patients.”

William ‘Obi’ M. Greenman President and CEO, Cerus.

 

View the video

Pathogen Reduced Cryoprecipitated Fibrinogen Complex

Visit product website

INTERCEPT® Blood System for Platelets and Plasma

Visit US SiteVisit International Site

At Cerus, we are proud of our consistent and unwavering focus to secure blood safety around the globe.

See Mission and Values

Annual Report

Annual Report 2021

Cerus’ Annual Meeting of Stockholders will be held online on Wednesday, June 5, 2024 at 8:00 a.m. Pacific Time.

Latest Press Releases

11/13/2024
Cerus Corporation to Participate in Upcoming Investor Conferences

10/30/2024
Cerus Corporation Announces Third Quarter 2024 Financial Results

10/16/2024
Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe

08/01/2024
Cerus Corporation Announces Second Quarter 2024 Financial Results and Increases Full-Year 2024 Product Revenue Guidance Range
07/18/2024
Cerus Corporation to Release Second Quarter 2024 Financial Results on August 1, 2024
07/02/2024
Cerus Corporation Announces Appointment of Dean Gregory to Board of Directors
06/21/2024
Cerus Corporation Announces Symposium and Abstracts at the 38th International Congress of the International Society of Blood Transfusion